Delineation of the frequency and boundary of chromosomal copy number variations in paediatric neuroblastoma
- 19 March 2018
- journal article
- research article
- Published by Taylor & Francis in Cell Cycle
- Vol. 17 (6) , 749-758
Abstract
Neuroblastoma, the most common solid tumour in early childhood, is characterized by very frequent chromosomal copy number variations (CNVs). While chromosome 2p amplification, 17q gain, 1p and 11q deletion in human neuroblastoma tissues are well-known, the exact frequencies and boundaries of the chromosomal CNVs have not been delineated. We analysed the publicly available single nucleotide polymorphism (SNP) array data which were originally generated by the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative, defined the frequencies and boundaries of chromosomes 2p11.2 – 2p25.3 amplification, 17q11.1-17q25.3 gain, 1p13.3-1p36.33 deletion and 11q13.3-11q25 deletion in neuroblastoma tissues, and identified chromosome 7q14.1 (Chr7:38254795-38346971) and chromosome 14q11.2 (Chr14:21637401-22024617) deletion in blood and bone marrow samples from neuroblastoma patients, but not in tumour tissues. Kaplan Meier analysis showed that double deletion of Chr7q14.1 and Chr14q11.2 correlated with poor prognosis in MYCN gene amplified neuroblastoma patients. In conclusion, the oncogenes amplified or gained and tumour suppressor genes deleted within the boundaries of chromosomal CNVs in tumour tissues should be studied for their roles in tumourigenesis and as therapeutic targets. Focal deletions of Chr7q14.1 and Chr14q11.2 together in blood and bone marrow samples from neuroblastoma patients can be used as a marker for poorer prognosis and more aggressive therapies.Keywords
Funding Information
- National Health & Medical Research Council
This publication has 28 references indexed in Scilit:
- NeuroblastomaNature Reviews Disease Primers, 2016
- Promising Therapeutic Targets in NeuroblastomaClinical Cancer Research, 2012
- Association of Age at Diagnosis and Genetic Mutations in Patients With NeuroblastomaJAMA, 2012
- NeuroblastomaAdvances in Pediatrics, 2011
- Somatic and germline activating mutations of the ALK kinase receptor in neuroblastomaNature, 2008
- Activating mutations in ALK provide a therapeutic target in neuroblastomaNature, 2008
- Oncogenic mutations of ALK kinase in neuroblastomaNature, 2008
- Identification of ALK as a major familial neuroblastoma predisposition geneNature, 2008
- Germline PHOX2B Mutation in Hereditary NeuroblastomaThe American Journal of Human Genetics, 2004
- Molecular Biology of NeuroblastomaJournal of Clinical Oncology, 1999